1. TuHURA Biosciences Inc. (NASDAQ:HURA)
TuHURA Biosciences Inc. (NASDAQ:HURA) is one of the unstoppable stocks that could double your money. TuHURA announced its financial results for Q4 and the full year. The company is advancing its Phase 3 trial for IFx-2.0 as an adjunctive treatment for Merkel Cell Carcinoma/MCC under an FDA Special Protocol Assessment, with enrollment expected to conclude in mid-2027. To support its development pipeline, TuHURA acquired Kineta’s VISTA-inhibiting antibody, TBS-2025, for $10.5 million and appointed Dr. Craig Tendler to provide oversight for clinical operations.
Significant corporate milestones include the initiation of a Phase 1b/2a study for IFx-2.0 in patients with metastatic MCC of unknown primary origin and the presentation of data at ASH identifying the Delta Opioid Receptor as a target for overcoming immunotherapy resistance. For 2026, the company expects to receive Orphan Drug Designation for IFx-2.0 in MCC and plans to meet with the FDA regarding TBS-2025’s development in AML. Additionally, TuHURA aims to select its lead antibody-drug conjugate and initiate proof-of-concept studies within the second half of the year.
TuHURA Biosciences Inc. (NASDAQ:HURA) reported $3.6 million in cash and cash equivalents at the end of 2025, supplemented by $7.5 million received in early 2026. Annual R&D expenses rose to $20.5 million, reflecting increased investment in its clinical programs compared to the previous year. The company successfully raised $21.2 million through private placements and offerings during this period, supporting its ongoing efforts to develop novel immuno-oncology therapeutics.
TuHURA Biosciences Inc. (NASDAQ:HURA) is a clinical-stage biotech firm that develops novel immuno-oncology technologies for cancer treatment. The company was formerly known as Morphogenesis until December 2023.
While we acknowledge the potential of HURA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HURA and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
